{
  "id": 8282636,
  "title": "Why the Next Billion Dollar Longevity Opportunity May Not Be a Product",
  "url": "https://urgent.news/2026/09/18/why-the-next-billion-dollar-longevity-opportunity-may-not-be-a-product",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-18T16:00:00.000Z",
  "source": {
    "name": "Entrepreneur",
    "slug": "entrepreneur",
    "url": "https://www.entrepreneur.com/entrepreneurs/why-the-next-billion-dollar-longevity-opportunity-may-not-be-a-product"
  },
  "original_language": "en",
  "account": null,
  "summary": "Longevity has no shortage of products, science, capital or consumer interest. The bottleneck is translation: getting promising science validated, understood by clinicians, implemented responsibly and ultimately to patients.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}